Insmed Incorporated (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 18,750 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the transaction, the chief executive officer now owns 384,960 shares in the company, valued at approximately $26,885,606.40. The trade was a 4.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
William Lewis also recently made the following trade(s):
- On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total value of $1,310,812.50.
Insmed Stock Down 0.1 %
Shares of Insmed stock traded down $0.09 during midday trading on Friday, hitting $69.86. The company had a trading volume of 1,151,144 shares, compared to its average volume of 1,046,072. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a market capitalization of $12.50 billion, a P/E ratio of -12.59 and a beta of 1.12. The company has a 50 day moving average of $71.62 and a 200 day moving average of $72.44.
Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analysts' expectations of $93.36 million. The company's revenue was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.10) earnings per share. On average, equities analysts predict that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on INSM shares. Truist Financial reissued a "buy" rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. Bank of America boosted their target price on Insmed from $84.00 to $86.00 and gave the company a "buy" rating in a research note on Wednesday, October 9th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a research note on Monday, September 9th. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $74.00 to $83.00 and gave the company an "overweight" rating in a report on Friday, November 22nd. Finally, HC Wainwright restated a "buy" rating and issued a $90.00 price objective on shares of Insmed in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $83.67.
Read Our Latest Research Report on INSM
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. CIBC Asset Management Inc bought a new stake in shares of Insmed during the second quarter valued at approximately $287,000. Rhumbline Advisers lifted its holdings in shares of Insmed by 13.9% during the second quarter. Rhumbline Advisers now owns 236,527 shares of the biopharmaceutical company's stock valued at $15,847,000 after purchasing an additional 28,865 shares in the last quarter. TD Asset Management Inc boosted its position in shares of Insmed by 23.1% during the second quarter. TD Asset Management Inc now owns 525,682 shares of the biopharmaceutical company's stock valued at $35,221,000 after buying an additional 98,504 shares during the last quarter. Victory Capital Management Inc. raised its position in Insmed by 672.7% in the 2nd quarter. Victory Capital Management Inc. now owns 147,140 shares of the biopharmaceutical company's stock worth $9,858,000 after buying an additional 128,098 shares during the last quarter. Finally, Arizona State Retirement System lifted its stake in Insmed by 5.7% during the 2nd quarter. Arizona State Retirement System now owns 39,491 shares of the biopharmaceutical company's stock valued at $2,646,000 after acquiring an additional 2,140 shares during the period.
Insmed Company Profile
(
Get Free Report)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Stories
Before you consider Insmed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.
While Insmed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
